Featured
Read our handpicked blogs, curated for you.
|
For Indian pharma, HCP engagement is no longer about reach; it’s about relevance and measurable impact. Boards want to…
|
Pharma marketing in India is at a turning point. Budgets have expanded, channels have multiplied, and compliance…
|
If you’re serious about HCP Engagement Tier 2 Cities, stop chasing metro playbooks. Tier 2 doctors don’t sit in front…
Recent releases
|
Winning HCP engagement beyond metro cities
Healthcare in India doesn’t stop at Mumbai, Delhi, or Bangalore. Beyond the metros lies the bulk of India’s medical ecosystem: doctors in Tier 2 and Tier 3 cities who prescribe at scale, influence…
|
Why pharma marketing still flies blind in India
Indian pharma marketing is at a crossroads. Budgets are rising, regulations are tightening, and digital adoption is accelerating. Yet when senior leaders are asked the simplest boardroom question: “…
|
The cost of slow content in pharma marketing and how to amplify it
Every pharma marketer knows the story. A campaign is planned around a new therapy, the slides are drafted, medical-legal-regulatory begins its review, weeks pass, edits keep coming back, and by the…
|
UCPMP 2024 changes pharma marketers must act on
For years, pharma marketing in India carried a reputation for being stuck between outdated field-force practices and patchy digital adoption. That space has shifted. UCPMP 2024 is not just an update…
